Tryptamine, 2,α-dimethyl · Indole, 2-methyl-3-(2-amino)propane · 2,α-Dimethyltryptamine · 2-Methyl-3-(2-amino)propylindole · 2-Me-α-MT · Alpha-2
#7 2,α-DMT SYNTHESIS: A solution of 4.78 g 2-methylindole-3-carboxaldehyde in 18 mL of nitroethane was treated with 0.77 g anhydrous ammonium acetate and heated on the steam bath for 2 h. The excess nitroethane was removed under vacuum and the residual orange-red solids were removed and washed with H2O. After drying these were triturated under 25 mL MeOH, filtered and air-dried to constant weight. There was thus obtained 3.8 g (59%) of 1-(2-methylindol-3-yl)-2-nitropropene with a mp 146–148 °C.
To 250 mL of a room-temperature 1.0 M solution of LAH in THF, well stirred and under N2, there was added a saturated solution of 3.6 g 1-(2-methylindol-3-yl)-2-nitropropene in warm THF. The addition took place over 1.25 h, the reaction mixture was stirred for an additional 8 h, and then held at 40 °C for 8 more h. The slurry was then cooled in an ice bath and decomposed by the slow, sequential addition of 30 mL isopropyl acetate, 20 mL H2O and, finally, 20 mL of 20% aqueous NaOH. The resulting alkaline suspension was extracted with 3×100 mL isopropyl acetate. The extracts were pooled, washed with 3×50 mL 10% aqueous NaOH, then extracted with 10% aqueous acetic acid. This extract was washed with isopropyl acetate, made basic with 20% aqueous NaOH, and extracted with 3×50 mL CHCl3. These extracts were pooled, dried with anhydrous Na2SO4 and, after removal of the drying agent by filtration, the solvent was removed under vacuum. The residual yellow oil was distilled under vacuum, at 150–160 °C at 1.8 mm/Hg, to give a pale yellow product. This was dissolved in a few mL MeOH and neutralized with a solution of fumaric acid in MeOH. The clear solution was heated and diluted with two volumes of hot isopropyl acetate. On cooling, fine white crystals of α,2-Dimethyltryptamine fumarate (2,α-DMT) were deposited. These were removed by filtration, and air-dried to constant weight. The yield was 1.64 g (60%) of a product with a mp of 209–211 °C.
DOSAGE: 300–500 mgs mg, orally
DURATION: 7–10 hrs h
QUALITATIVE COMMENTS: (with 200 mgs mg, orally) “I feel just a little bit intoxicated. Probably few if any effects.”
(with 300 mgs mg, orally) “It was an hour before I realized that something was happening. Very subtle, some tingling of the face, the lights are somehow brighter. Really laid back, try to let my fantasy go with closing my eyes and sitting quietly, but it mostly just felt good to sit quiet. I feel that I am on the edge of something here, but I see it slipping away. ”
(with 450 mgs mg, orally) “It was almost as if I had had a drink too many. I was feeling good, but I tried turning the dial on the radio to find music, and the fine motor coordination in my hands was not there. My thinking was completely clear, and the music I finally found was fine for day-dreaming. There were some flashes on the edge of my visual field and things seemed to feel softer and richer. Eating was a quite an adventure in tastes, but I really couldn’t eat much. Very peaceful, and an easy sleep took over at about the 13th hour. Next day, still pretty dehydrated. All in all, it was a very nice experience.”
EXTENSIONS AND COMMENTARY: I do love the satisfying feeling that comes with the successful assignment of a pharmacological change as a function of a single structural change. This is the holy grail of every SAR enthusiast (SAR = Structure Activity Relationship). Make a change in structure, see a corresponding change in activity. There is a correlation. There is causality. And there you have a new, firmly established fact of science to add to the understanding of the universe.
A case in point. What happens when you put a methyl group on the two-position of the indole ring of a tryptamine. In the three examples, examples of the best studied tryptamines that were not active orally, they all became orally active. , and , the three major parenterally-only active psychedelics, all blossomed into orally active compounds with the addition of a simple methyl group to that indole 2-position. As I had smugly argued, in the discussions of , and Indapex , it is as if that bit of bulk got in the way of the destructive amine oxidases, and protected the molecule from its expected first-pass metabolic destruction.
So what happens here? You take a compound, , that is already immune to this oxidase system and is already orally active. Add a 2-methyl group to give 2-Me-α-MT, or 2,α-DMT. And what happens? The potency goes down, not up, and by a factor of 10 times. And it ends up being more of a sedative than a stimulant. So much for generalities. I suspect that I do not understand the universe nearly as well as I thought I did.
13 May 2016 · Creative Commons BY-NC-SA ·

About TiHKAL · info

This version of Book II of TiHKAL is based on the Erowid online version created by Bo Lawler with the help of Erowid, from content generously provided in electronic format by the Authors.
The Erowid online version does not always align precisely with the printed version. Text appears to have been inserted, deleted, or changed at various points. Where the two are seen to diverge both the Erowid and print versions are given. Sharp-eyed readers are encouraged to report novel discrepancies.
As with PiHKAL, I’ve again attempted to reproduce the typographic style of the printed edition. I’ve again made minor changes to some chemical names in line with current nomenclature practice. Typically the change is little more than expanding a prefix or setting it in italics. The history page has further details.

Cautionary note

“At the present time, restrictive laws are in force in the United States and it is very difficult for researchers to abide by the regulations which govern efforts to obtain legal approval to do work with these compounds in human beings.
“No one who is lacking legal authorization should attempt the synthesis of any of the compounds described in these files, with the intent to give them to man. To do so is to risk legal action which might lead to the tragic ruination of a life. It should also be noted that any person anywhere who experiments on himself, or on another human being, with any of the drugs described herein, without being familiar with that drug’s action and aware of the physical and/or mental disturbance or harm it might cause, is acting irresponsibly and immorally, whether or not he is doing so within the bounds of the law.”
Alexander T. Shulgin

Copyright notice

The copyright for Book I of TiHKAL has been reserved in all forms and it may not be distributed. Book II of TiHKAL may be distributed for non-commercial reproduction provided that the introductory information, copyright notice, cautionary notice and ordering information remain attached.

Ordering information

TiHKAL is the extraordinary record of the authors’ years exploring the chemistry and transformational power of tryptamines. This book belongs in the library of anyone seeking a rational, enlightened and candid perspective on psychedelic drugs.
Though Sasha and Ann have put Book II of TiHKAL in the public domain, available to anyone, I strongly encourage you to buy a copy. We owe them — and there’s still nothing quite like holding a real book in your hands.
TiHKAL (ISBN 0-9630096-9-9) is available for US$24.50 (plus $10 domestic first-class shipping) from Transform Press.
Transform Press,
Box 13675
Berkeley, CA 94701

510 · 934 · 4930 (voice)
510 · 934 · 5999 (fax)